Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436337 | 0.86 | F10 (0.56) | F10KCNH2KLKB1 | |
| SCHEMBL2436471 | 0.82 | F10 (0.60) | F10KCNH2KLKB1 | |
| SCHEMBL13313049 | 0.82 | F10 (0.67) | F10KCNH2KLKB1 | |
| SCHEMBL13313056 | 0.80 | F10 (0.62) | F10KCNH2KLKB1 | |
| SCHEMBL15855152 | 0.80 | F10 (0.78) | F10KCNH2KLKB1 | |
| SCHEMBL19527197 | 0.80 | F10 (0.78) | F10KCNH2KLKB1 | |
| SCHEMBL13312990 | 0.80 | F10 (0.67) | F10KCNH2KLKB1 | |
| SCHEMBL8353486 | 0.80 | F10 (0.66) | F10KCNH2KLKB1 | |
| SCHEMBL2494633 | 0.79 | F10 (0.63) | F10KCNH2KLKB1 | |
| SCHEMBL13313055 | 0.78 | F10 (0.68) | F10KCNH2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708265-B2 | Urethanes, ureas, amidines and related inhibitors of factor Xa | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2017-07-18 | — | — | US | disclosed |
| EP-2542529-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | Tovbin, Dmitry Gennadievich (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2013-01-03 | — | — | US | disclosed |
| WO-2011108963-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | TOVBIN DMITRY GENNADIEVICH (RU) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PLAUR, PLAU, UTS2R | F10 9/4885KCNH2 1486/4885KLKB1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.